Vir's hepatitis D drug combo hits Phase 3 goal

Vir Biotechnology said Sunday its combination drug cleared a major hurdle. In a late-stage trial, patients got monthly shots of two drugs, elebsiran and tobevibart. After 48 weeks, 44% had no detectable hepatitis D virus left in their blood. Patients who waited to start treatment saw 0% reach that mark. The company calls the trial a success. It hasn't been independently reviewed yet.

Hepatitis D is a rough disease to have. It only infects people who already have hepatitis B, and it speeds up liver damage when it does. Today's main treatment, Gilead's Hepcludex, doesn't work for everyone — that's part of why doctors want more options. A real alternative, especially one that gets to undetectable levels, would matter to patients who've had almost no good options. Competitors Gilead and Mirum Pharmaceuticals are watching closely. This result raises the bar for what a hepatitis D drug needs to do.

Keep reading — what to watch

Will this hold up once regulators see the full data? That's the real test. Topline numbers from a company's own announcement sometimes look better than they turn out once the FDA digs in. Watch for Vir to file for approval, and watch whether Gilead or Mirum answer with their own new trial results. Hepatitis D patients haven't had a real race between drugmakers before. They might be about to get one.